KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in IntangiblesChange in InventoryDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for BioNTech SE (BNTX) over the last 7 years, with Q3 2025 value amounting to $32.6 million.

  • BioNTech SE's Share-based Compensation fell 2738.49% to $32.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.3 million, marking a year-over-year increase of 1771.57%. This contributed to the annual value of $107.8 million for FY2024, which is 9496.35% up from last year.
  • As of Q3 2025, BioNTech SE's Share-based Compensation stood at $32.6 million, which was down 2738.49% from $36.3 million recorded in Q2 2025.
  • Over the past 5 years, BioNTech SE's Share-based Compensation peaked at $73.6 million during Q3 2021, and registered a low of $20.87 during Q1 2021.
  • Its 5-year average for Share-based Compensation is $26.0 million, with a median of $22.6 million in 2022.
  • Over the last 5 years, BioNTech SE's Share-based Compensation had its largest YoY gain of 26944123966.81% in 2021, and its largest YoY loss of 9999.98% in 2021.
  • Over the past 5 years, BioNTech SE's Share-based Compensation (Quarter) stood at $23.5 million in 2021, then decreased by 3.42% to $22.6 million in 2022, then plummeted by 32.54% to $15.3 million in 2023, then skyrocketed by 64.36% to $25.1 million in 2024, then increased by 29.88% to $32.6 million in 2025.
  • Its Share-based Compensation was $32.6 million in Q3 2025, compared to $36.3 million in Q2 2025 and $23.2 million in Q1 2025.